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Carsten Nieder1,2*, Adam Pawinski1 and Astrid Dalhaug1,2Abstract
Recent studies from Italy, Japan and Norway have confirmed previous reports, which found that a large variety of
palliative radiotherapy regimens are used for painful bone metastases. Routine use of single fraction treatment
might or might not be the preferred institutional approach. It is not entirely clear why inter-physician and inter-
institution differences continue to persist despite numerous randomized trials, meta-analyses and guidelines, which
recommend against more costly and inconvenient multi-fraction regimens delivering total doses of 30 Gy or more
in a large number of clinical scenarios. In the present mini-review we discuss the questions of whether doctors are
ignoring evidence-based medicine or whether we need additional studies targeting specifically those patient
populations where recent surveys identified inconsistent treatment recommendations, e.g. because of challenging
disease extent. We identify open questions and provide research suggestions, which might contribute to making
radiation oncology practitioners more confident in selecting the right treatment for the right patient.
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Most radiotherapy facilities worldwide are treating large
numbers of patients with bone metastases from solid
tumors. Over the last decades, numerous prospective
randomized trials have confirmed the high efficacy of
radiation treatment in terms of pain relief. The presence
of pain does not seem to be correlated with the type of
tumor, location, number or size of the metastases [1,2].
For localized pain, radiotherapy is a well-accepted treat-
ment modality with a 60-80% likelihood of overall pain
relief reported [3-5]. The mechanism of response remains
unknown. Because the onset of pain relief is often rapid,
within days, it is not likely to be dependent upon tumor* Correspondence: carsten.nieder@nlsh.no
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reproduction in any medium, provided the orshrinkage alone. It is probable that a response mechanism
through modification of chemical mediators is important.
Different palliative radiotherapy schedules have been
studied, ranging from a single fraction of 6 or 8 Gy, to
20 Gy in 5 fractions, 24 Gy in 6 fractions, 30 Gy in 10
fractions and even 40 Gy in 20 fractions [6-22]. No clear
dose effect relationship has been seen in any of these
trials. Subsequent meta-analyses have confirmed the
equal effectiveness of a single dose schedule compared to
more protracted regimens [3,23,24]. Based on acute
toxicity rates, convenience and cost/benefit ratio, a single
fraction of 8 Gy is therefore considered to be the preferred
radiotherapy schedule for patients with uncomplicated
bone pain, that is for bone lesions not causing neuro-
logical complaints and without a high risk of pathological
fracture. Among the randomized trials comparing single
versus multiple fractions for painful bone metastases,
retreatment rates were consistently higher after the singleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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single fraction to 0-24% after multiple fractions.
If complicated by spinal canal invasion or compression
of the spinal cord, common practice in most western
countries is to deliver 20 Gy in 5 fractions in patients
with a minimum life expectancy of 3 months, or 30 Gy
in 10 fractions in patients with a more prolonged life
expectancy (minimum 1 year) [25-28]. Single fraction
treatment might be considered in patients with a prog-
nosis less than 3 months.
Recent data on utilization of single fraction radiotherapy
In Japan, members of the Japanese Radiation Oncology
Study Group (JROSG) were invited to complete an
Internet-based survey and describe the radiotherapy dose/
fractionation they would recommend for 4 hypothetical
cases [29]. Case 1 described a patient with an uncompli-
cated painful bone metastasis in a non-weight-bearing site
from non-small-cell lung cancer. Case 2 investigated
whether management for a case of uncomplicated spinal
metastasis would be different from that in case 1. Case 3
was identical with case 2 except for the presence of
neuropathic pain. Case 4 investigated the prescription for
an uncomplicated painful bone metastasis secondary to
oligometastatic breast cancer. A total of 52 radiation on-
cologists from 50 institutions responded. In all four cases,
the most commonly prescribed regimen was 30 Gy in 10
fractions. Single fraction irradiation was recommended by
13% of respondents for case 1, 6% for case 2, 0% for case
3, and 2% for case 4.
A comparable survey was distributed in Italy to deter-
mine the decision patterns of Italian radiation oncolo-
gists in 4 different clinical cases of patients with bone
metastases [30]. Again, the cases were different with
respect to the histology of the primary tumor (breast,
prostate and lung cancer), and in addition performance
status, pain before and after analgesics, tumor site, and
radiological characteristics of the metastatic lesions. One
hundred twenty-two questionnaires were adequately com-
pleted and considered for the analysis. Single fraction
radiotherapy was the preferred option in a minority of
respondents in each case (ranging from 9-30%). Major
factors influencing choice of dose/fractionation regimen
included prognosis, performance status, metastatic site and
radiological appearance of the lesion. Financial aspects,
personal habits and departmental waiting lists were not
among these factors (<7% of responses for each factor).
A different Internet-based survey was distributed to
the members of 3 radiation oncology professional orga-
nizations (American Society for Radiology Oncology
[ASTRO], Canadian Association of Radiation Oncology
[CARO], Royal Australian and New Zealand College of
Radiologists) [31]. It included 5 hypothetical patients
with single or multiple painful metastases from breast,lung, or prostate cancer, plus two reirradiation scenarios.
A total of 962 respondents, three-quarters ASTRO
members, described 101 different dose schedules in
common use. The median dose overall was 30 Gy in 10
fractions. Single fraction schedules were used the least
often by ASTRO members practicing in the United
States (3-16%) and most often by CARO members (17%,
31%, 38%, 56% and 69% in the 5 cases). Case, member-
ship affiliation, country of training, location of practice,
and practice type were independently predictive of the
use of single fraction radiotherapy. The principal factors
considered when prescribing were prognosis, risk of
spinal cord compression, and performance status.
French speaking physicians from different European
countries (n=644) also answered a questionnaire on bone
metastases management [32]. Only 54% used short course
radiotherapy in routine. Of 35 African centers contacted
in a different study, 24 (68%) completed the questionnaire
[33]. Fourteen centers had a single fractionation regimen
as an institutional policy for treating painful bone metasta-
ses (one size fits all approach), whereof 5 centers (21%)
used 8 Gy single fraction. Further surveys from different
time periods and countries exist but these are not neces-
sary to describe clinical practice because results were
comparable to those already reviewed.
A different approach was taken in Norway, where a
national registry-based study was conducted, including all
radiotherapy schedules of 8 Gy single dose and 30 Gy in
10 fractions (1997–2007) [34]. A total of 14,380 radiother-
apy courses were identified. During the time period 31%
of the treatments were delivered as single fraction. The
proportion of single fraction treatments increased from
16% in 1997 to 41% in 2007. There were substantial dif-
ferences in the proportion of single fraction treatments
between the treatment centers (range 25-54%). These
differences persisted after adjustment for sex, age, primary
diagnosis, anatomical region, and travel distance.
In a Canadian study, electronic records from the nine
provincial radiotherapy centers in Ontario were linked to
the Ontario Cancer Registry to identify all courses of
palliative radiotherapy for bone metastases [35]. Between
1984 and 2001, 44,884 patients received 74,432 courses.
The mean number of fractions per course was 3.9. The
proportion of patients treated with a single fraction
increased from 27% in 1984–1986 to 40% in 1987–1992
and decreased thereafter. Single fractions were used more
frequently in patients with a shorter life expectancy, in
older patients, and in patients who lived further from a
radiotherapy facility. Single fractions were used more
frequently when the prevailing waiting time was longer.
Discussion
As shown above [29-31], the use of single fraction radio-
therapy depends on patient- and disease-related factors.
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tries and treatment facilities. The optimal utilization rate
is unknown and depends on case mix, but could possibly
be as high as the 54% reported as the highest rate in one
Norwegian center. The Japanese and U.S. figures (<20%)
were strikingly different and indicate under-utilization
even if they are not related to actual patient treatments.
What are the possible explanations for these variations
in pattern of care? The landmark randomized trials and
meta-analyses have been discussed and published exten-
sively, including editorials and oral presentations at all
national and international radiation oncology meetings.
So, poor knowledge distribution and education are
unlikely to explain the discrepancy between scientific
evidence and clinical practice. Possibly, single fraction
treatment does not fulfill some patients' expectation
regarding high tech radiation oncology in a time of
public discussion around protons, robotic radiosurgery
and other developments. To improve this obstacle,
better communication and patient information might be
necessary. Previous studies suggested that most patients
were not familiar with the concept of radiation treat-
ment and that approximately 40% believed that palliative
radiotherapy would prolong their life [36,37]. Up to 25%
believed their cancer was curable.
Is it likely that variations in systemic cancer treatment
influence fractionation concepts, need for, and efficacy
of palliative radiotherapy for bone metastases? It has
become common practice to administer bisphospho-
nates or denosumab, which reduce the likelihood of
skeletal-related events (pathologic fracture, spinal cord
compression, need for surgery and radiotherapy). At the
same time, improved chemotherapy, endocrine treat-
ment, and new targeted agents are able to extend
survival of patients with metastastic cancer, thereby
increasing the time period during which skeletal-related
events might occur. The latter development might
prevent radiotherapy utilization rates from declining, but
the focus of this article is on fractionation. In theory,
systemic therapy might act additive to radiotherapy and
could replace a certain amount of dose while still
maintaining the same level of efficacy. Moreover, initial
use of systemic therapy might delay referral to radiother-
apy and shift the patient population towards a heavier
pretreated and maybe more recalcitrant state. The litera-
ture contains limited confirmatory information. A Japanese
study of breast cancer patients with spinal column
metastases suggested that local control and survival after
radiotherapy were better in the absence of previous
chemotherapy [38]. There is ample opportunity for pro-
spective research projects on this subject because most
previous studies provided little information about the
interplay of systemic therapy and irradiation, and there is
also rapid introduction of new drugs and regimens indiseases such as breast, prostate, kidney and bowel cancer.
There is currently no high evidence data proofing that one
particular fractionation regimen provides advantages over
others in the most common scenarios, for example
castration-resistant prostate cancer, endocrine responsive
breast cancer, Her2 positive breast cancer, EGFR wild-type
non-small cell lung cancer, clear cell kidney cancer treated
with angiogenesis inhibitors etc. In certain situations, it
might be advantageous that shorter courses of radiotherapy
interfere less with administration dates of systemic treat-
ment. However, all these issues require additional studies.
Going back to the combination of radiotherapy and
bisphosphonates, Canadian data suggested that use of
bisphosphonates has not reduced the utilization rates of
palliative radiotherapy in breast cancer patients with bone
metastases [39]. There was a trend of initiating bisphos-
phonates before delivery of palliative radiotherapy.
A Turkish randomized study (also limited to breast
cancer) suggested that high-dose palliative radiotherapy
was equally effective as reduced-dose irradiation when
used concomitantly with zoledronic acid [40]. A second,
non-randomized study (different primary tumors) con-
firmed this finding and suggested that bisphosphonates
did not have any additive effects on pain palliation in the
management of painful bone metastases with radio-
therapy [41]. It is therefore unlikely that variations in
systemic treatment are the major reason for the large
differences in utilization of single fraction radiotherapy.
Another potential reason is financial incentives, even if
not confirmed by the responses of Italian survey partici-
pants (apparently this question was not addressed in the
other surveys). If reimbursement of single fraction radio-
therapy is worse than that of a course of multiple frac-
tions, it might be more attractive to prescribe a longer
course. Clearly this issue depends on health care system,
reimbursement rates and departmental waiting lists or
patient prioritization. In Norway (all patients covered by
the National Health Care system, no private radiation on-
cology providers), reimbursement actually was influenced
in part by number of fractions. Nevertheless single frac-
tion use was quite common [34]. Because of inadequate
nationwide capacity and lower than recommended general
utilization of radiotherapy (estimated need was 55% of all
cancer patients as described in the National Cancer Treat-
ment Program), waiting lists existed in all radiotherapy
departments despite operating at maximum capacity. It
was therefore not possible to increase the departmental
revenue by prolonging palliative radiotherapy series. Any
such attempt would have caused a disadvantageous
increase in waiting time. The considerations discussed
here provide arguments for creating reimbursement
scenarios that remove incentives for prolonged fractio-
nation regimens. However, the situation is complex
because there is obvious agreement in all radiation
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studies shown earlier, that a general "less is more" ap-
proach is not warranted. In other words, one size (in this
case single fraction radiotherapy) does not fit all patients.
Recent guidelines appreciate the fact that any treatment
recommendation must fit the individual need of a given
patient, and that we have to choose appropriately from
several fractionation options [42-44]. If there is a medical
need for more intense radiotherapy despite of higher
economic burden (an example of cost-effectiveness is
given in [45]), any additional operating expense should
also be reimbursed. For the purpose of this mini-review,
we will not discuss the ability to deliver single fraction or
hypofractionated stereotactic body radiotherapy to certain
metastatic sites [46,47]. The basic dilemma also relates to
stereotactic techniques: if certain medical indications for
more intense radiotherapy exist, how can these be clearly
defined and agreed on?
The question can also be rephrased: Have previous
studies given us all the answers we need? One of the
randomized studies was performed at the first author’s
previous institution [15]. Even if no single fraction arm
was included, it highlights the challenges of previous
bone metastases research. We included patients with all
types of solid primary tumors, different bone and extra-
osseous disease extent, location in pelvis, spine, ribs andFigure 1 Computed tomography scan in a patient with adenocarcino
bone pain (bone lesions not causing neurological complaints and wit
extension: treated with 8 Gy x1.so on, and in different disease trajectories (bone me-
tastases at first cancer diagnosis in treatment-naïve
patients, heavily pre-treated patients without further
systemic treatment options etc.), in other words, all
those patients practicing radiation oncologists meet du-
ring a typical month. Prognosis differed but should this
fact influence our choice of fractionation regimen? In
the prospective randomized Dutch bone metastasis
study (single fraction of 8 Gy versus 24 Gy in six frac-
tions), 28% of the patients survived for more than 1 year
[48]. In these 320 patients with better prognosis,
responses were 87% after 8 Gy and 85% after 24 Gy
(p=0.54). Duration of response and progression rates
were similar. For all primary tumors, prognostic factors
for survival were good performance status, no visceral
metastases, and non-opioid analgesics intake.
Figures 1, 2, 3 and 4 show the broad variation of local
disease extent, another factor considered by many physi-
cians. Most likely, more radiation oncologists might be
reluctant to use single fraction radiotherapy in examples
3 and 4 (large volume disease and/or threat to spinal
cord) especially if the patients' survival expectation is
not limited to 2–3 months, they are ambulatory and in
good general condition. The randomized trials have not
specifically addressed patient populations with large
volume disease, which consist of some patients withma of the prostate, multiple bone metastases and uncomplicated
hout a high risk of pathological fracture), no extra-osseous
Figure 2 Computed tomography scan in a patient with clear cell kidney cancer and uncomplicated bone pain (bone lesions not
causing neurological complaints and without a high risk of pathological fracture), extra-osseous extension present (white arrow),
known lung and adrenal gland metastases: treated with 8 Gy x1.
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neurological complaints and without a high risk of
pathological fracture) and some patients with impending
fracture or spinal cord compression. For reasons includ-
ing but not limited to medico-legal issues no uniform
international threshold for definition of impending
spinal cord compression or increased fracture risk exists.
Performing retrospective analyses of older randomized
trials that identify such challenging patients is difficult
and methodologically inferior to conducting trials limited
to narrowly defined patient groups and including all rele-
vant endpoints. Future trials could also shed light on other
interesting questions many practitioners are struggling
with: does the higher biologically effective dose of more
intense regimens truly provide more extensive tumor
remission and/or superior local control (remember that
pain relief is not clearly related to pre-treatment or longi-
tudinal imaging findings) and if so, do serial imaging find-
ings eventually translate into clinically measurable benefit?
At the end of the day we care for patients with limited
survival expectation and complex disease states, which
impair quality of life at different levels. Can we achieve the
same outcome by reirradiating those patients who do not
experience long-lasting benefit after their first course of
radiotherapy?We hypothesize that most clinicians already prescri-
bing single fractions to many but not all of their patients
are making careful decisions based on many clinical vari-
ables. They try to assign the right patient to the right
treatment. Yet not all of these variables might be truly
relevant, and future studies should also aim at develop-
ment of decision aids that are just as complex as needed,
become generally accepted and part of treatment guide-
lines. Both radiation oncology communities and bone
metastasis experts should support studies providing the
evidence that will allow practitioners to escape the current
dilemma of often subjective treatment recommendations.
It is unfortunate that comparable patients receive hete-
rogeneous treatment even within well defined regions (for
example Ontario [35]) or tightly regulated and centralized
cancer care systems with small populations (for example
Norway [34]). In Ontario, single fractions were used more
frequently in patients who lived further from a radiother-
apy facility and when the prevailing waiting time was
longer [35]. How should these factors be weighted when
deciding about treatment, both on an individual patient
basis and a more general level (who pays for transportation
and accommodation, is access to curative radiotherapy
threatened by a wealth of patients receiving long-course
palliative treatment)? We believe it is possible to perform
Figure 3 Computed tomography scan in a patient with adenocarcinoma of the lung (no EGFR mutation) and bone pain (bone lesion
causing weakness of the right lower limb, initial manifestation of this lung malignancy, treatment-naïve), massive extra-osseous
extension present: treated with 3 Gy x10.
Figure 4 Computed tomography scan in a patient with squamous cell lung cancer (no EGFR mutation, known lung metastases) and
uncomplicated bone pain (no neurological complaints), extra-osseous extension and spinal canal invasion present: treated with 3 Gy x10.
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http://www.ro-journal.com/content/8/1/85additional studies that will better define which patients
cannot be adequately managed with a single fraction of 8
Gy, which is considered to be the preferred radiotherapy
schedule for patients with uncomplicated bone pain, and
to determine the optimum regimen for these patients.
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